Adding IL-2 to Tebentafusp to Eradicate Cancer Progression
Adding IL-2 to Tebentafusp to Eradicate Cancer Progression
Recruiting · NCT07063875 · Registry updated 2025-07-14Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Adding IL-2 to Tebentafusp to Eradicate Cancer Progression | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Uveal Neoplasms, eye disorder, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, ocular cancer, primitive neuroectodermal tumor, uveal disorder, uveal melanoma | Recruiting | Phase 1 / Phase 2 | 2025-07-14 | NCT07063875 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| St Vincent's Hospital, Sydney | 9 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Alfred Hospital | Melbourne | Australia | 30 |
| Kinghorn Cancer Centre, St. Vincent's Hospital | Sydney | Australia | 3 |